Physician profile
Cody Kidd
NPI 1508516873
$819.28
in general payments reported to CMS, 2019-2025
21 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.20 · 2023: $128 · 2024: $273 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $253.62 | 2023-2025 | |
| Novo Nordisk INC | $83.36 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $45.83 | 2024-2025 | Mounjaro, Trulicity, Zepbound |
| Sanofi-Aventis U.S. LLC | $42.45 | 2024 | |
| Dexcom, INC. | $36.17 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $34.38 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.94 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $33.13 | 2025 | Airsupra |
| Abbott Laboratories | $31.36 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $27.84 | 2025 | Repatha, Otezla |
| Inari Medical, INC. | $22.85 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Corcept Therapeutics | $22.67 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $22.40 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $22.08 | 2025 | Recorlev |
| Axsome Therapeutics, INC. | $19.41 | 2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16.37 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.96 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.36 | 2023 | Xifaxan |
| Cvrx, INC. | $14.05 | 2024 | Barostim Neo System |
| Astellas Pharma US INC | $13.85 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.